The reply

Joseph G. Verbalis; Steven Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W. Schrier; Richard H. Sterns; Chris J. Thompson

doi:10.1016/j.amjmed.2014.03.022

The reply

Joseph G. Verbalis
, Steven Goldsmith
, Arthur Greenberg
, Cynthia Korzelius
, Robert W. Schrier
, Richard H. Sterns
, Chris J. Thompson

Medicine - Cardiology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	e31-e32
Journal	American Journal of Medicine
Volume	127
Issue number	7
DOIs	https://doi.org/10.1016/j.amjmed.2014.03.022
State	Published - Jul 2014

Bibliographical note

Funding Information:
Conflict of Interest: SRG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc. AG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc., and Cornerstone Therapeutics. CK has no potential conflicts of interest to disclose. RWS has served as a consultant for Otsuka America Pharmaceutical, Inc., and Janssen Pharmaceutical. RHS has no potential conflicts of interest to disclose. JGV has received grant support from Otsuka America Pharmaceutical, Inc., as well as non-CME-related fees from Otsuka America Pharmaceutical, Inc., Cardiokine, and Cornerstone Therapeutics. CJT has served as a consultant for Otsuka European Pharmaceuticals.

Funding Information:
Funding: The supplement referred to in this letter was, in part, based on a closed roundtable meeting that was held in October 2012 in New York City and was jointly sponsored by the Tufts University School of Medicine Office of Continuing Education and In 2 MedEd, LLC, through an unrestricted educational grant from Otsuka America Pharmaceutical, Inc.

Publisher link

10.1016/j.amjmed.2014.03.022

Find It

Find It at U of M Libraries

Cite this

@article{32b47b6d1f614362b23d95485c9bcb1c,

title = "The reply",

author = "Verbalis, \{Joseph G.\} and Steven Goldsmith and Arthur Greenberg and Cynthia Korzelius and Schrier, \{Robert W.\} and Sterns, \{Richard H.\} and Thompson, \{Chris J.\}",

note = "Funding Information: Conflict of Interest: SRG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc. AG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc., and Cornerstone Therapeutics. CK has no potential conflicts of interest to disclose. RWS has served as a consultant for Otsuka America Pharmaceutical, Inc., and Janssen Pharmaceutical. RHS has no potential conflicts of interest to disclose. JGV has received grant support from Otsuka America Pharmaceutical, Inc., as well as non-CME-related fees from Otsuka America Pharmaceutical, Inc., Cardiokine, and Cornerstone Therapeutics. CJT has served as a consultant for Otsuka European Pharmaceuticals. Funding Information: Funding: The supplement referred to in this letter was, in part, based on a closed roundtable meeting that was held in October 2012 in New York City and was jointly sponsored by the Tufts University School of Medicine Office of Continuing Education and In 2 MedEd, LLC, through an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. ",

year = "2014",

month = jul,

doi = "10.1016/j.amjmed.2014.03.022",

language = "English (US)",

volume = "127",

pages = "e31--e32",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - The reply

AU - Verbalis, Joseph G.

AU - Goldsmith, Steven

AU - Greenberg, Arthur

AU - Korzelius, Cynthia

AU - Schrier, Robert W.

AU - Sterns, Richard H.

AU - Thompson, Chris J.

N1 - Funding Information: Conflict of Interest: SRG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc. AG has received grant support and non-CME-related fees from Otsuka America Pharmaceutical, Inc., and Cornerstone Therapeutics. CK has no potential conflicts of interest to disclose. RWS has served as a consultant for Otsuka America Pharmaceutical, Inc., and Janssen Pharmaceutical. RHS has no potential conflicts of interest to disclose. JGV has received grant support from Otsuka America Pharmaceutical, Inc., as well as non-CME-related fees from Otsuka America Pharmaceutical, Inc., Cardiokine, and Cornerstone Therapeutics. CJT has served as a consultant for Otsuka European Pharmaceuticals. Funding Information: Funding: The supplement referred to in this letter was, in part, based on a closed roundtable meeting that was held in October 2012 in New York City and was jointly sponsored by the Tufts University School of Medicine Office of Continuing Education and In 2 MedEd, LLC, through an unrestricted educational grant from Otsuka America Pharmaceutical, Inc.

PY - 2014/7

Y1 - 2014/7

UR - https://www.scopus.com/pages/publications/84903189536

UR - https://www.scopus.com/pages/publications/84903189536#tab=citedBy

U2 - 10.1016/j.amjmed.2014.03.022

DO - 10.1016/j.amjmed.2014.03.022

M3 - Letter

C2 - 24970609

AN - SCOPUS:84903189536

SN - 0002-9343

VL - 127

SP - e31-e32

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 7

ER -

The reply

Bibliographical note

Publisher link

Find It

Other files and links

Cite this